NSCLC accounts for 85 percent of lung cancer cases in the United States. Five year survival stands at 65 percent when the disease remains localized yet falls to 9 percent after distant spread. Screening detects 80 percent of cases at stage I or II among high risk groups while targeted therapies extend median survival beyond 30 months in mutation positive patients.
Key Takeaways
- CT screening detects 80% of NSCLC at stage I-II in high-risk groups.
- NSCLC accounts for approximately 85% of all lung cancer cases diagnosed in the United States.
- 5-year survival for stage IA NSCLC post-resection is 83-92%.
- Smoking causes 80-90% of NSCLC cases worldwide.
- Surgery (lobectomy) is standard for stage I NSCLC, resectability 70-80%.
NSCLC remains common, and survival varies widely by stage, making early detection crucial for better outcomes.
Related reading
01 · Category
Diagnosis and Detection20 stats
01
CT screening detects 80% of NSCLC at stage I-II in high-risk groups.
02
Low-dose CT reduces NSCLC mortality by 20% in heavy smokers (NLST trial).
03
PET-CT staging accuracy for NSCLC mediastinal nodes is 85-90%.
04
EBUS-TBNA sensitivity for N2/N3 staging in NSCLC is 89%.
05
Liquid biopsy detects EGFR mutations in 70-90% of advanced NSCLC plasma samples.
06
PD-L1 expression by IHC (TPS ≥50%) in 25-30% of NSCLC cases.
07
Next-generation sequencing identifies actionable mutations in 60% of advanced NSCLC.
08
Bronchoscopy diagnostic yield for peripheral NSCLC nodules is 70%.
09
Electromagnetic navigation bronchoscopy improves yield to 85% for small nodules.
10
CT-guided biopsy complication rate (pneumothorax) is 15-25%.
11
Tumor markers like CYFRA 21-1 elevated in 60% of squamous NSCLC.
12
MRI brain detects asymptomatic metastases in 10-20% of stage III NSCLC.
13
8th AJCC staging: T1a ≤1cm, 5-year survival 92%.
14
N1 nodal involvement (ipsilateral peribronchial) in 20-30% stage II NSCLC.
15
M1c distant metastases (multiple organs) in 40% advanced NSCLC.
16
IASLC 8th edition reclassifies 20% of previous stage IIIB to IIIA NSCLC.
17
Circulating tumor DNA (ctDNA) detects relapse 3-4 months earlier in 75% cases.
18
ROS1 fusion detected in 1-2% NSCLC by FISH or NGS.
19
RET fusions in 1-2% NSCLC, more in never-smokers.
20
NTRK fusions rare at 0.1-1% but targetable in NSCLC.
Interpretation
Diagnosis and Detection Interpretation
While early screening catches most lung cancers while they're still curable, the real battle is a relentless molecular chess match where we're armed with increasingly precise, minimally invasive tools to profile, stage, and target a wily disease that constantly tries to outflank us.
02 · Category
Epidemiology20 stats
01
NSCLC accounts for approximately 85% of all lung cancer cases diagnosed in the United States.
02
In 2023, an estimated 238,340 new cases of lung cancer were diagnosed in the US, with NSCLC comprising about 117,550 cases assuming 85% proportion.
03
The age-adjusted incidence rate of NSCLC in the US from 2016-2020 was 33.1 per 100,000 men and 27.5 per 100,000 women.
04
Globally, lung cancer incidence in 2020 was 2.2 million cases, with NSCLC estimated at 80-85% or about 1.76-1.87 million cases.
05
In Europe, NSCLC incidence rates vary by country, with highest in Hungary at 52.3 per 100,000 for men in 2020.
06
NSCLC prevalence in the US survivor population is around 600,000 individuals living with lung cancer as of 2023.
07
The incidence of NSCLC has declined by 2.6% annually in US men from 2012-2021 due to reduced smoking.
08
In women, NSCLC incidence rates stabilized at 31.3 per 100,000 from 2015-2019.
09
Asian populations show lower NSCLC incidence at 20.4 per 100,000 compared to whites at 38.2.
10
NSCLC is the most common lung cancer subtype in never-smokers, comprising 60-80% of cases.
11
In China, NSCLC accounts for 75% of lung cancers with 815,563 new cases in 2022.
12
US mortality from NSCLC is projected at 125,070 deaths in 2023 out of 127,070 lung cancer deaths.
13
Incidence of adenocarcinoma subtype of NSCLC is 40% of all lung cancers.
14
Squamous cell carcinoma subtype incidence is 25-30% of NSCLC cases.
15
Large cell carcinoma represents 5-10% of NSCLC diagnoses globally.
16
NSCLC median age at diagnosis is 70 years in the US population.
17
Only 16% of NSCLC cases are diagnosed at localized stage.
18
Regional stage NSCLC accounts for 22% of diagnoses.
19
Distant metastatic NSCLC comprises 57% at diagnosis.
20
Unknown stage NSCLC is 5% of cases.
Interpretation
Epidemiology Interpretation
While non-small cell lung cancer is the dominant form of the disease, its sobering global reign is marked by a frustratingly late diagnosis for most, reminding us that prevalence is not the same as prevention.
03 · Category
Prognosis and Survival18 stats
01
5-year survival for stage IA NSCLC post-resection is 83-92%.
02
Stage IB resected NSCLC 5-year survival 68-77%.
03
Stage II resected NSCLC median survival 40-50 months.
04
Stage IIIA unresectable NSCLC with CRT: 3-year survival 25-30%.
05
Metastatic NSCLC median survival without treatment 4-5 months.
06
EGFR TKI first-line in mutant NSCLC: OS 30-38 months.
07
ALK inhibitors improve median OS to 45-50 months vs 20 months chemo.
08
Immunotherapy in PD-L1 high: 5-year OS 31.9% (KEYNOTE-001).
09
Overall 5-year relative survival for NSCLC 28% (2013-2019).
10
Localized NSCLC 5-year survival 65%.
11
Regional NSCLC 5-year survival 37%.
12
Distant NSCLC 5-year survival 9%.
13
Postoperative recurrence rate in stage I NSCLC 20-30% within 5 years.
14
Brain metastases develop in 25-50% of advanced NSCLC patients.
15
Performance status ECOG 0-1 predicts median survival >12 months in metastatic NSCLC.
16
Female sex associated with 10-15% better survival in NSCLC.
17
Never-smoker status improves OS by 20% in advanced NSCLC.
18
Adenocarcinoma histology has better prognosis than squamous (HR 0.85).
Interpretation
Prognosis and Survival Interpretation
The stark reality of NSCLC survival is a sobering chess match where early surgery can yield a long victory, but advanced disease requires a precise combination of modern targeted moves and immunological gambits just to buy meaningful time.
More related reading
04 · Category
Risk Factors20 stats
01
Smoking causes 80-90% of NSCLC cases worldwide.
02
Current smokers have a 15-30 times higher risk of developing NSCLC compared to never-smokers.
03
Secondhand smoke exposure increases NSCLC risk by 20-30% in non-smokers.
04
Radon exposure is linked to 21,000 lung cancer deaths annually in US, mostly NSCLC.
05
Asbestos exposure increases NSCLC risk 5-fold, especially with smoking synergy.
06
Air pollution (PM2.5) associated with 8-14% increased NSCLC risk per 10ug/m3 increase.
07
Family history doubles the risk of NSCLC in first-degree relatives.
08
EGFR mutations prevalent in 10-15% of NSCLC in Western populations, higher in Asians at 30-50%.
09
KRAS mutations found in 25-30% of NSCLC adenocarcinomas, strongly linked to smoking.
10
ALK rearrangements in 3-7% of NSCLC, more common in never-smokers under 50.
11
Obesity (BMI>30) increases NSCLC risk by 30-50% in never-smokers.
12
Chronic obstructive pulmonary disease (COPD) raises NSCLC risk 4-5 fold.
13
Previous lung diseases like pneumonia increase risk by 1.5-2 times.
14
Occupational silica exposure linked to 20-30% higher NSCLC incidence.
15
Diesel exhaust exposure increases NSCLC risk by 40% in highly exposed workers.
16
Beta-carotene supplements in smokers increase NSCLC risk by 18%.
17
Low fruit/vegetable intake associated with 15% higher NSCLC risk.
18
Alcohol consumption >3 drinks/day raises risk by 20%.
19
Hormonal factors: postmenopausal estrogen use increases risk by 25%.
20
Welding fumes exposure linked to 30% increased NSCLC odds.
Interpretation
Risk Factors Interpretation
While humanity’s creativity in finding ways to inflate lung cancer risk—from lighting up a cigarette to simply breathing polluted air or living in a basement with radon—is impressively grim, it’s sobering to realize that quitting smoking remains the single most powerful act of rebellion against this statistical fate.
05 · Category
Treatment Modalities17 stats
01
Surgery (lobectomy) is standard for stage I NSCLC, resectability 70-80%.
02
Stereotactic body radiotherapy (SBRT) local control 90-95% for inoperable stage I NSCLC.
03
Adjuvant cisplatin-vinorelbine improves 5-year survival by 5% in stage II-IIIA.
04
Concurrent chemoradiation (CRT) for stage III NSCLC: median survival 28 months.
05
Pembrolizumab monotherapy ORR 45% in PD-L1 ≥50% advanced NSCLC (KEYNOTE-024).
06
Osimertinib median PFS 18.9 months in EGFR-mutant advanced NSCLC (FLAURA).
07
Alectinib ORR 62% vs crizotinib 45% in ALK-positive NSCLC.
08
Bevacizumab + chemo PFS 6.2 vs 4.5 months in non-squamous NSCLC.
09
Durvalumab consolidation after CRT: PFS 16.8 vs 5.6 months (PACIFIC).
10
Carboplatin-paclitaxel doublet response rate 20-30% in first-line advanced NSCLC.
11
Neoadjuvant nivolumab + chemo major pathologic response 36% in resectable NSCLC.
12
Proton therapy reduces cardiac toxicity by 50% vs photon in stage III NSCLC.
13
Lorlatinib intracranial ORR 66% in pretreated ALK+ NSCLC.
14
Sotorasib ORR 37.1% in KRAS G12C-mutant advanced NSCLC.
15
Adagrasib PFS 6.5 months in KRAS G12C NSCLC (KRYSTAL-1).
16
Selpercatinib ORR 64% in RET-fusion NSCLC.
17
Entrectinib ORR 77% in ROS1+ NSCLC.
Interpretation
Treatment Modalities Interpretation
In lung cancer treatment, surgeons cut, radiation zaps, and a menagerie of drugs—from pembrolizumab to sotorasib—now target specific mutations, proving that while removing the tumor is a powerful opening act, the real headliners are the increasingly precise therapies that turn a once blunt fight into a remarkably targeted siege.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Marie Larsen. (2026, February 13). Nsclc Statistics. Gitnux. https://gitnux.org/nsclc-statistics
MLA
Marie Larsen. "Nsclc Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/nsclc-statistics.
Chicago
Marie Larsen. 2026. "Nsclc Statistics." Gitnux. https://gitnux.org/nsclc-statistics.
Sources & references
12 datasets cited across this report · attribution is report-level